Bradley Canino
Stock Analyst at Stifel
(1.92)
# 2,955
Out of 4,681 analysts
89
Total ratings
32.47%
Success rate
-5.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AFMD Affimed | Maintains: Hold | $5 → $4 | $2.78 | +43.88% | 5 | Nov 15, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $40 → $41 | $16.70 | +145.51% | 5 | Oct 14, 2024 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $11.20 | +69.64% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $12.63 | +232.54% | 4 | Oct 7, 2024 | |
| SMMT Summit Therapeutics | Maintains: Buy | $25 → $40 | $18.49 | +116.33% | 4 | Sep 25, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Buy | $28 | $4.67 | +499.57% | 4 | Sep 16, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $115 → $135 | $94.27 | +43.21% | 4 | Sep 16, 2024 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $20 | $10.17 | +96.66% | 1 | Sep 6, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $70 | $40.18 | +74.22% | 1 | Sep 6, 2024 | |
| ALXO ALX Oncology Holdings | Reiterates: Hold | $5 → $3 | $1.66 | +80.72% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.00 | +400.00% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $3.66 | +173.22% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $99 | $48.53 | +104.00% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $4.30 | +225.58% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $68 | $25.72 | +164.39% | 5 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $13.17 | +203.72% | 1 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $130 | $97.62 | +33.17% | 5 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $47.74 | +15.21% | 4 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $10 | $2.59 | +286.10% | 4 | Jun 30, 2023 |
Affimed
Nov 15, 2024
Maintains: Hold
Price Target: $5 → $4
Current: $2.78
Upside: +43.88%
Syndax Pharmaceuticals
Oct 14, 2024
Maintains: Buy
Price Target: $40 → $41
Current: $16.70
Upside: +145.51%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $11.20
Upside: +69.64%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $12.63
Upside: +232.54%
Summit Therapeutics
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $18.49
Upside: +116.33%
Relay Therapeutics
Sep 16, 2024
Reiterates: Buy
Price Target: $28
Current: $4.67
Upside: +499.57%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $94.27
Upside: +43.21%
ORIC Pharmaceuticals
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $10.17
Upside: +96.66%
Janux Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $70
Current: $40.18
Upside: +74.22%
ALX Oncology Holdings
Aug 9, 2024
Reiterates: Hold
Price Target: $5 → $3
Current: $1.66
Upside: +80.72%
Aug 8, 2024
Initiates: Buy
Price Target: $10
Current: $2.00
Upside: +400.00%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $3.66
Upside: +173.22%
Jun 17, 2024
Maintains: Buy
Price Target: $90 → $99
Current: $48.53
Upside: +104.00%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $4.30
Upside: +225.58%
May 8, 2024
Maintains: Buy
Price Target: $72 → $68
Current: $25.72
Upside: +164.39%
May 1, 2024
Initiates: Buy
Price Target: $40
Current: $13.17
Upside: +203.72%
Apr 26, 2024
Maintains: Buy
Price Target: $120 → $130
Current: $97.62
Upside: +33.17%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $47.74
Upside: +15.21%
Jun 30, 2023
Upgrades: Buy
Price Target: $2 → $10
Current: $2.59
Upside: +286.10%